S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
NASDAQ:ONCY

Oncolytics Biotech Stock Forecast, Price & News

$2.55
-0.17 (-6.25 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.50
Now: $2.55
$2.74
50-Day Range
$2.32
MA: $2.70
$4.03
52-Week Range
$0.94
Now: $2.55
$4.19
Volume2.01 million shs
Average Volume1.42 million shs
Market Capitalization$106.23 million
P/E RatioN/A
Dividend YieldN/A
Beta2.75
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

MarketRank

Overall MarketRank

1.18 out of 5 stars

Medical Sector

843rd out of 1,923 stocks

Pharmaceutical Preparations Industry

421st out of 773 stocks

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCY
CUSIPN/A
CIKN/A
Phone403-670-7377
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-24,960,000.00

Miscellaneous

Market Cap$106.23 million
Next Earnings Date3/4/2021 (Estimated)
OptionableNot Optionable
$2.55
-0.17 (-6.25 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ONCY News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Oncolytics Biotech (NASDAQ:ONCY) Frequently Asked Questions

How has Oncolytics Biotech's stock been impacted by COVID-19 (Coronavirus)?

Oncolytics Biotech's stock was trading at $1.74 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ONCY stock has increased by 46.6% and is now trading at $2.55.
View which stocks have been most impacted by COVID-19
.

Is Oncolytics Biotech a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Oncolytics Biotech stock.
View analyst ratings for Oncolytics Biotech
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Oncolytics Biotech?

Wall Street analysts have given Oncolytics Biotech a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oncolytics Biotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Brad Thompson's approval rating as Oncolytics Biotech's CEO?

2 employees have rated Oncolytics Biotech CEO Brad Thompson on Glassdoor.com. Brad Thompson has an approval rating of 56% among Oncolytics Biotech's employees. This puts Brad Thompson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Oncolytics Biotech's next earnings date?

Oncolytics Biotech is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Oncolytics Biotech
.

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech Inc. (NASDAQ:ONCY) issued its quarterly earnings data on Monday, November, 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.06.
View Oncolytics Biotech's earnings history
.

What price target have analysts set for ONCY?

4 equities research analysts have issued 1-year price objectives for Oncolytics Biotech's stock. Their forecasts range from $6.00 to $9.00. On average, they expect Oncolytics Biotech's share price to reach $7.33 in the next twelve months. This suggests a possible upside of 187.6% from the stock's current price.
View analysts' price targets for Oncolytics Biotech
or view Wall Street analyst' top-rated stocks.

Who are some of Oncolytics Biotech's key competitors?

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), KushCo (KSHB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Cannabics Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

Who are Oncolytics Biotech's key executives?

Oncolytics Biotech's management team includes the following people:
  • Dr. Matthew C. Coffey, Pres, CEO & Director
  • Mr. Kirk J. Look C.A., CA, Chief Financial Officer
  • Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 53)
  • Mr. John Mark Lievonen B.B.A., F.C.A., M.B.A., CM, FCPA, FCA, LLD, Consultant
  • Dr. Thomas C. Heineman M.D., Ph.D., Global Head of Clinical Devel. & Operations
  • Jon Patton, Director of Investor Relations & Communication
  • Dr. Grey Wilkinson Ph.D., Scientist of Translational Medicine
  • Dr. Daniel Douglas Von Hoff M.D., F.A.C.P., Consultant (Age 72)

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the NASDAQ under the ticker symbol "ONCY."

Who are Oncolytics Biotech's major shareholders?

Oncolytics Biotech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include International Assets Investment Management LLC (0.29%).

Which major investors are buying Oncolytics Biotech stock?

ONCY stock was acquired by a variety of institutional investors in the last quarter, including International Assets Investment Management LLC.

How do I buy shares of Oncolytics Biotech?

Shares of ONCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oncolytics Biotech's stock price today?

One share of ONCY stock can currently be purchased for approximately $2.55.

How big of a company is Oncolytics Biotech?

Oncolytics Biotech has a market capitalization of $106.23 million. The company earns $-24,960,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

What is Oncolytics Biotech's official website?

The official website for Oncolytics Biotech is www.oncolyticsbiotech.com.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. The company can be reached via phone at 403-670-7377 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.